References
- American Diabetes Association. "9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020." Diabetes care43.Supplement 1 (2020): S98-S110.
- Arnett, Donna K., et al. "2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines." Journal of the American College of Cardiology74.10 (2019): e177-e232.
- Baptist, Gallwitz. "The Cardiovascular Benefits Associated with the Use of Sodium-Glucose Cotransporter 2 Inhibitors–Real-World Data." European Endocrinology14.1 (2018): 17.
- Bhatt, Deepak L., Subodh Verma, and Eugene Braunwald. "The DAPA-HF trial: a momentous victory in the war against heart failure." Cell metabolism30.5 (2019): 847-849.
- Centers for Disease Control and Prevention. 2020 National Diabetes Statistics Report. https://www.cdc.gov/diabetes/data/statistics/national-diabetes-statistics-report.pdf. Accessed January September 23, 2020.
- Cherney, David Z., et al. "Sodium Glucose Cotransporter-2 Inhibition and Cardiorenal Protection: JACC Review Topic of the Week." Journal of the American College of Cardiology74.20 (2019): 2511-2524.
- Das, Sandeep R., et al. "2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee." Journal of the American College of Cardiology76.9 (2020): 1117-1145.
- Dekkers, Claire CJ, and Ron T. Gansevoort. "Sodium-glucose cotransporter 2 inhibitors: extending the indication to non-diabetic kidney disease?." Nephrology Dialysis Transplantation35.Supplement_1 (2020): i33-i42.
- Ehrenkranz, Joel RL, et al. "Phlorizin: a review." Diabetes/metabolism research and reviews21.1 (2005): 31-38.
- Kieffer, Cameron M., and Andrew S. Robertson. "Impact of FDA-required cardiovascular outcome trials on type 2 diabetes clinical study initiation from 2008 to 2017." Therapeutic Innovation & Regulatory Science(2020): 1-5.
- McMurray, John JV. "EMPEROR‐Reduced: Confirming sodium‐glucose cotransporter 2 (SGLT2) inhibitors as an essential treatment for patients with heart failure with reduced ejection fraction." European Journal of Heart Failure (2020).
- Neal, Bruce, et al. "Canagliflozin and cardiovascular and renal events in type 2 diabetes." New England Journal of Medicine377.7 (2017): 644-657.
- Packer, Milton, et al. "Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure." New England Journal of Medicine(2020).
- Perkovic, Vlado, et al. "Canagliflozin and renal outcomes in type 2 diabetes and nephropathy." New England Journal of Medicine380.24 (2019): 2295-2306.
- Perkovic, Vlado, et al. "Renal effects of canagliflozin in type 2 diabetes mellitus." Current medical research and opinion31.12 (2015): 2219-2231.
- Saran, Rajiv, et al. "US Renal Data System 2016 annual data report: epidemiology of kidney disease in the United States." American journal of kidney diseases69.3 (2017): A7-A8.
- Verma, Subodh, Peter Jüni, and C. David Mazer. "Pump, pipes, and filter: do SGLT2 inhibitors cover it all?." The Lancet393.10166 (2019): 3-5.
- Wiviott, Stephen D., et al. "Dapagliflozin and cardiovascular outcomes in type 2 diabetes." New England Journal of Medicine(2018).
- Zelniker, Thomas A., and Eugene Braunwald. "Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors in diabetes: JACC state-of-the-art review." Journal of the American College of Cardiology72.15 (2018): 1845-1855.
- Zelniker, Thomas A., and Eugene Braunwald. "Mechanisms of cardiorenal effects of sodium-glucose cotransporter 2 inhibitors: JACC state-of-the-art review." Journal of the American College of Cardiology75.4 (2020): 422-434.
- Zinman, Bernard, et al. "Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes." New England Journal of Medicine373.22 (2015): 2117-2128.